|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GLG1 |
Gene summary for GLG1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GLG1 | Gene ID | 2734 |
| Gene name | golgi glycoprotein 1 | |
| Gene Alias | CFR-1 | |
| Cytomap | 16q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q92896 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2734 | GLG1 | CA_HPV_3 | Human | Cervix | CC | 4.32e-05 | 1.01e-01 | 0.0414 |
| 2734 | GLG1 | N_HPV_2 | Human | Cervix | N_HPV | 1.50e-02 | 5.79e-02 | -0.0131 |
| 2734 | GLG1 | CCI_1 | Human | Cervix | CC | 4.94e-02 | 5.14e-01 | 0.528 |
| 2734 | GLG1 | CCI_2 | Human | Cervix | CC | 3.50e-09 | 1.20e+00 | 0.5249 |
| 2734 | GLG1 | CCI_3 | Human | Cervix | CC | 1.02e-07 | 8.70e-01 | 0.516 |
| 2734 | GLG1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.10e-09 | 6.63e-01 | -0.0811 |
| 2734 | GLG1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.41e-04 | 5.54e-01 | -0.1088 |
| 2734 | GLG1 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.08e-24 | 7.62e-01 | -0.1954 |
| 2734 | GLG1 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.53e-04 | 7.16e-01 | -0.2602 |
| 2734 | GLG1 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.80e-03 | 4.08e-01 | -0.1464 |
| 2734 | GLG1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.91e-06 | 6.09e-01 | -0.059 |
| 2734 | GLG1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 9.54e-03 | 4.29e-01 | 0.0588 |
| 2734 | GLG1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.68e-02 | 7.55e-01 | 0.3487 |
| 2734 | GLG1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.11e-13 | 8.34e-01 | 0.281 |
| 2734 | GLG1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.02e-02 | 5.66e-01 | 0.3859 |
| 2734 | GLG1 | A015-C-203 | Human | Colorectum | FAP | 7.71e-28 | -1.82e-01 | -0.1294 |
| 2734 | GLG1 | A015-C-204 | Human | Colorectum | FAP | 9.51e-04 | -1.83e-01 | -0.0228 |
| 2734 | GLG1 | A014-C-040 | Human | Colorectum | FAP | 1.49e-03 | -3.00e-01 | -0.1184 |
| 2734 | GLG1 | A002-C-201 | Human | Colorectum | FAP | 7.48e-10 | -1.34e-01 | 0.0324 |
| 2734 | GLG1 | A002-C-203 | Human | Colorectum | FAP | 3.97e-02 | 1.61e-02 | 0.2786 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:006034821 | Oral cavity | NEOLP | bone development | 38/2005 | 205/18723 | 5.28e-04 | 4.64e-03 | 38 |
| GO:005160432 | Oral cavity | NEOLP | protein maturation | 50/2005 | 294/18723 | 6.46e-04 | 5.47e-03 | 50 |
| GO:001648521 | Oral cavity | NEOLP | protein processing | 39/2005 | 225/18723 | 1.68e-03 | 1.17e-02 | 39 |
| GO:00020621 | Oral cavity | NEOLP | chondrocyte differentiation | 22/2005 | 106/18723 | 1.72e-03 | 1.19e-02 | 22 |
| GO:0051216 | Oral cavity | NEOLP | cartilage development | 32/2005 | 190/18723 | 6.44e-03 | 3.32e-02 | 32 |
| GO:00487051 | Oral cavity | NEOLP | skeletal system morphogenesis | 36/2005 | 220/18723 | 6.47e-03 | 3.33e-02 | 36 |
| GO:004586118 | Prostate | BPH | negative regulation of proteolysis | 98/3107 | 351/18723 | 5.43e-08 | 1.49e-06 | 98 |
| GO:00715597 | Prostate | BPH | response to transforming growth factor beta | 76/3107 | 256/18723 | 1.14e-07 | 2.73e-06 | 76 |
| GO:00715607 | Prostate | BPH | cellular response to transforming growth factor beta stimulus | 72/3107 | 250/18723 | 8.71e-07 | 1.61e-05 | 72 |
| GO:00516049 | Prostate | BPH | protein maturation | 80/3107 | 294/18723 | 2.64e-06 | 4.23e-05 | 80 |
| GO:00071797 | Prostate | BPH | transforming growth factor beta receptor signaling pathway | 57/3107 | 198/18723 | 1.17e-05 | 1.58e-04 | 57 |
| GO:00071788 | Prostate | BPH | transmembrane receptor protein serine/threonine kinase signaling pathway | 90/3107 | 355/18723 | 1.48e-05 | 1.90e-04 | 90 |
| GO:00164855 | Prostate | BPH | protein processing | 62/3107 | 225/18723 | 2.22e-05 | 2.67e-04 | 62 |
| GO:19038445 | Prostate | BPH | regulation of cellular response to transforming growth factor beta stimulus | 37/3107 | 131/18723 | 5.57e-04 | 3.89e-03 | 37 |
| GO:00170154 | Prostate | BPH | regulation of transforming growth factor beta receptor signaling pathway | 36/3107 | 128/18723 | 7.16e-04 | 4.76e-03 | 36 |
| GO:0090287 | Prostate | BPH | regulation of cellular response to growth factor stimulus | 70/3107 | 304/18723 | 2.18e-03 | 1.21e-02 | 70 |
| GO:00603483 | Prostate | BPH | bone development | 50/3107 | 205/18723 | 2.60e-03 | 1.39e-02 | 50 |
| GO:00900923 | Prostate | BPH | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 59/3107 | 256/18723 | 4.51e-03 | 2.19e-02 | 59 |
| GO:004586119 | Prostate | Tumor | negative regulation of proteolysis | 102/3246 | 351/18723 | 3.09e-08 | 9.94e-07 | 102 |
| GO:007155915 | Prostate | Tumor | response to transforming growth factor beta | 76/3246 | 256/18723 | 6.86e-07 | 1.40e-05 | 76 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa045147 | Cervix | CC | Cell adhesion molecules | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
| hsa0451412 | Cervix | CC | Cell adhesion molecules | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
| hsa0451441 | Cervix | N_HPV | Cell adhesion molecules | 18/349 | 157/8465 | 7.71e-05 | 8.06e-04 | 6.30e-04 | 18 |
| hsa0451451 | Cervix | N_HPV | Cell adhesion molecules | 18/349 | 157/8465 | 7.71e-05 | 8.06e-04 | 6.30e-04 | 18 |
| hsa045146 | Lung | IAC | Cell adhesion molecules | 30/1053 | 157/8465 | 1.03e-02 | 3.83e-02 | 2.54e-02 | 30 |
| hsa0451411 | Lung | IAC | Cell adhesion molecules | 30/1053 | 157/8465 | 1.03e-02 | 3.83e-02 | 2.54e-02 | 30 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| SELE | GLG1 | SELE_GLG1 | SELE | Breast | ADJ |
| SELE | GLG1 | SELE_GLG1 | SELE | Breast | Healthy |
| SELE | GLG1 | SELE_GLG1 | SELE | Cervix | ADJ |
| SELE | GLG1 | SELE_GLG1 | SELE | Cervix | CC |
| SELE | GLG1 | SELE_GLG1 | SELE | Endometrium | ADJ |
| SELE | GLG1 | SELE_GLG1 | SELE | Endometrium | AEH |
| SELE | GLG1 | SELE_GLG1 | SELE | Endometrium | EEC |
| SELE | GLG1 | SELE_GLG1 | SELE | Esophagus | ESCC |
| SELE | GLG1 | SELE_GLG1 | SELE | GC | Healthy |
| SELE | GLG1 | SELE_GLG1 | SELE | HNSCC | ADJ |
| SELE | GLG1 | SELE_GLG1 | SELE | HNSCC | Healthy |
| SELE | GLG1 | SELE_GLG1 | SELE | HNSCC | OSCC |
| SELE | GLG1 | SELE_GLG1 | SELE | HNSCC | Precancer |
| SELE | GLG1 | SELE_GLG1 | SELE | Prostate | ADJ |
| SELE | GLG1 | SELE_GLG1 | SELE | Prostate | BPH |
| SELE | GLG1 | SELE_GLG1 | SELE | Prostate | Healthy |
| SELE | GLG1 | SELE_GLG1 | SELE | Prostate | Tumor |
| SELE | GLG1 | SELE_GLG1 | SELE | Skin | ADJ |
| SELE | GLG1 | SELE_GLG1 | SELE | Skin | AK |
| SELE | GLG1 | SELE_GLG1 | SELE | Skin | cSCC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GLG1 | SNV | Missense_Mutation | c.1717C>G | p.Arg573Gly | p.R573G | Q92896 | protein_coding | deleterious(0.01) | possibly_damaging(0.524) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| GLG1 | SNV | Missense_Mutation | novel | c.2081N>A | p.Arg694Lys | p.R694K | Q92896 | protein_coding | tolerated(0.25) | possibly_damaging(0.553) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
| GLG1 | SNV | Missense_Mutation | rs763398161 | c.1621N>A | p.Asp541Asn | p.D541N | Q92896 | protein_coding | tolerated(0.2) | benign(0.122) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| GLG1 | SNV | Missense_Mutation | novel | c.3442C>A | p.Leu1148Ile | p.L1148I | Q92896 | protein_coding | tolerated(0.12) | probably_damaging(0.986) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GLG1 | SNV | Missense_Mutation | c.2171N>G | p.Asn724Ser | p.N724S | Q92896 | protein_coding | tolerated(0.05) | probably_damaging(0.939) | TCGA-D8-A1JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| GLG1 | deletion | Frame_Shift_Del | c.2499_2500delCT | p.Phe833LeufsTer32 | p.F833Lfs*32 | Q92896 | protein_coding | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR | |||
| GLG1 | SNV | Missense_Mutation | novel | c.3331C>T | p.Arg1111Cys | p.R1111C | Q92896 | protein_coding | deleterious(0.01) | probably_damaging(0.95) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GLG1 | SNV | Missense_Mutation | c.623N>A | p.Arg208Gln | p.R208Q | Q92896 | protein_coding | tolerated(0.12) | possibly_damaging(0.749) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| GLG1 | SNV | Missense_Mutation | novel | c.2575T>C | p.Cys859Arg | p.C859R | Q92896 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| GLG1 | SNV | Missense_Mutation | c.1043G>A | p.Ser348Asn | p.S348N | Q92896 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |